Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04431453 · ClinicalTrials.gov registry record · Phase 2

Study of Remdesivir in Participants Below 18 Years Old With COVID-19

A Phase 2 study, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target

NCT04431453: Completed Phase 2 study, sponsored by Gilead Sciences.

NCT04431453 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04431453, a Phase 2 study, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target

Study Summary

The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).

Primary Outcome

TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.

Interventions

  • DRUG Remdesivir

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2020-07-21
Est. Completion 2023-02-10
Phase Phase 2
Gilead Sciences

504 total trials

What the finished NCT04431453 record still lists

NCT04431453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).

The record links to 0 conditions, and to 1 intervention - of which Remdesivir is the first listed.

NCT04431453 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04431453 about?

NCT04431453 is a clinical study titled "Study of Remdesivir in Participants Below 18 Years Old With COVID-19". The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).

What is the current status of trial NCT04431453?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2020-07-21. Estimated completion is 2023-02-10.

What interventions are being tested in trial NCT04431453?

The interventions under investigation include: Remdesivir (DRUG).

Who is sponsoring clinical trial NCT04431453?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04431453's enrollment target sits among peer trials

59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03801083 · 59 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

  • NCT04332367 · 59 participants · Phase 2

    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • NCT05489575 · 59 participants · NA

    CPAP for the Treatment of Supine Hypertension

  • NCT06721689 · 59 participants · Phase 1

    PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04431453, the US trial registry maintained by the National Library of Medicine. NCT04431453 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.